B. Metzler Seel. Sohn & Co. Holding Ag Ligand Pharmaceuticals Inc Call Options Transaction History
B. Metzler Seel. Sohn & Co. Holding Ag
- $10.1 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LGND
# of Institutions
249Shares Held
18MCall Options Held
61KPut Options Held
7.8K-
Black Rock Inc. New York, NY2.87MShares$347 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.97MShares$238 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.01MShares$122 Million0.05% of portfolio
-
Macquarie Group LTD Australia, C3967KShares$117 Million0.1% of portfolio
-
Dimensional Fund Advisors LP Austin, TX707KShares$85.4 Million0.02% of portfolio
About LIGAND PHARMACEUTICALS INC
- Ticker LGND
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 16,882,800
- Market Cap $2.04B
- Description
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...